Feature | November 22, 2010

Trends in Radiation Oncology From ASTRO 2010

Radiation oncology as a profession is in a period of retrenchment due to the economic crisis. There is also a growing demand from payors to show value for these treatments, said ASTRO President Anthony Zeitman, M.D. He says the technologies used need to undergo rigorous clinical testing to show what works best and what is most cost-effective. Part of ASTRO's push is for a national registry to help advance this data collection.

Related Content

A look at ITN's top-viewed content for April 2024
Feature | Radiology Business | By Melinda Taschetta-Millane
Top 10: What Viewers Were Reading in April

One on One interviews with radiology trailblazers and historic FDA clearances made the top-read list for April. Take a ...

Time May 03, 2024
arrow
Advances in the growing radiation dose management market are continually helping those who administer treatment to focus on personalized patient care and workflow management
Feature | Radiation Dose Management | By Christine Book
Radiation Dose Management Market Overview and Product Updates

Advances in the growing radiation dose management market are continually helping those who administer treatment to focus ...

Time May 03, 2024
arrow
This acquisition signifies Radformation’s commitment to driving innovation and expanding its AI-driven capabilities in cancer care.
News | Artificial Intelligence
Radformation to Accelerate AI-Based Solutions with Limbus AI Acquisition

May 2, 2024 — Radformation, Inc., a leader in automation solutions for cancer care, announced today that it has acquired ...

Time May 02, 2024
arrow
Extending beyond brain tumors, empowering patients with treatment options in prostate cancer and other malignancies
News | Prostate Cancer
GT Medical Technologies, Inc and Theragenics Corporation Forge Distribution Partnership for Cesium-131

May 2, 2024 — GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the ...

Time May 02, 2024
arrow
The study, led by principal investigator Nitin Ohri, M.D., a professor in Radiation Oncology at the Montefiore Einstein Comprehensive Cancer Center, aims to demonstrate the feasibility of PGHD collection during proton beam radiotherapy for lung cancer
News | Proton Therapy
Koneksa Announces Study with New York Proton Center to Collect Patient-Generated Health Data During Proton Radiotherapy in Lung Cancer

April 29, 2024 — Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today ...

Time April 29, 2024
arrow
Elekta Instrument AB recalls disposable biopsy needle kit for Leksell Stereotactic System for possibly containing microscopic stainless steel febris on the inside of the biopsy needle
News | FDA
FDA Announces Elekta Recall of Biopsy Needle Kit for Leksell Stereotactic System

April 29, 2024 — The U.S. Food and Drug Administration (FDA) announced Elekta Instrument AB is recalling Disposable ...

Time April 29, 2024
arrow
New partnership makes outstanding radiation protection solutions available to healthcare professionals
News | Radiation Dose Management
BIOTRONIK and Texray Establish Collaboration to Distribute Texray’s Innovative Radiation Protection Products

April 25, 2024 — BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and ...

Time April 25, 2024
arrow
News | Radiation Therapy
Accuray Expands Global Training Center Network With Opening of New Facility in Genolier, Switzerland

April 18, 2024 — Accuray Incorporated announced that as part of its commitment to advancing patient care the company has ...

Time April 18, 2024
arrow
LUMISIGHT and Lumicell Direct Visualization System (DVS) offer 84% diagnostic accuracy in detecting residual cancer, in real-time, that may have been otherwise missed during lumpectomy surgery, while sparing some from second surgeries
News | FDA
Lumicell’s Cutting-Edge Imaging Platform Receives Historic FDA Approval to Illuminate Residual Breast Cancer

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
A Medicare policy requiring primary care providers (PCPs) to share in the decision-making with patients on whether to proceed with lung cancer screening is fraught with confusion and lack of evidence-based information, and may actually be undermining the purpose for which it was created
News | Lung Imaging
Mount Sinai Study Calls for Major Changes in the Way People With Comorbidities Are Selected by Physicians for Lung Cancer Screening

April 17, 2024 — A Medicare policy requiring primary care providers (PCPs) to share in the decision-making with patients ...

Time April 17, 2024
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now